Earnings calendar/RXRX
Recursion Pharmaceuticals, Inc. (RXRX)
Pre-earnings consensus targets and post-earnings beat/miss — standardized metrics from the earnings calendar. No narrative, no price targets.
Pre-earnings
Consensus targets for the next print, plus how the business has been running.
Next report
Nov 4, 2026
Consensus estimate row
EPS target
$-0.22
Street estimate
Revenue target
$14.2M
Street estimate
Trailing EPS (avg 4Q)
$-0.26
Beat rate last 4: 75%
Latest EPS YoY
+39.0%
vs 2025-08-05
Latest revenue YoY
-61.8%
How results look so far
Trailing revenue (avg 4Q)
$13.5M
Printed quarters
EPS beat rate (4Q)
75%
Share of quarters that beat EPS est.
Post-earnings
Did the company hit the target? Actual vs estimate and surprise.
Last print
Aug 5, 2026
EPS miss
EPS actual / est
$-0.25 / $-0.24
-4.2%
Revenue actual / est
$7.3M / $11.0M
-33.4%
Result
Below target
Based on EPS vs consensus
Earnings history
Estimate vs actual and surprise % by print date
| Date | EPS est | EPS act | EPS surprise | Rev est | Rev act | Rev surprise |
|---|---|---|---|---|---|---|
| 11/4/2026upcoming | $-0.22 | Pending | — | $14.2M | Pending | — |
| 8/5/2026 | $-0.24 | $-0.25 | -4.2% | $11.0M | $7.3M | -33.4% |
| 5/6/2026 | $-0.30 | $-0.22 | +26.7% | $15.8M | $6.3M | -60.1% |
| 5/4/2026upcoming | $-0.27 | Pending | — | $17.5M | Pending | — |
| 2/27/2026upcoming | $-0.34 | Pending | — | — | Pending | — |
| 2/25/2026 | $-0.28 | $-0.21 | +25.0% | $24.5M | $35.4M | +44.0% |
| 11/5/2025 | $-0.38 | $-0.36 | +5.3% | $24.6M | $5.2M | -78.9% |
| 8/5/2025 | $-0.35 | $-0.41 | -17.1% | $19.9M | $19.1M | -4.1% |
| 5/5/2025 | $-0.44 | $-0.50 | -13.6% | $14.0M | $14.7M | +5.6% |
| 2/28/2025 | $-0.44 | $-0.53 | -20.5% | $19.0M | $4.5M | -76.3% |
| 11/6/2024 | $-0.33 | $-0.34 | -3.0% | $18.2M | $26.1M | +43.5% |
| 8/8/2024 | $-0.35 | $-0.40 | -14.3% | $13.3M | $14.4M | +8.7% |
| 5/9/2024 | $-0.43 | $-0.39 | +9.3% | $12.7M | $13.8M | +9.0% |
| 2/27/2024 | $-0.46 | $-0.40 | +13.0% | $20.4M | $10.9M | -46.5% |
| 11/9/2023 | $-0.38 | $-0.43 | -13.2% | $20.5M | $10.1M | -50.8% |
| 8/8/2023 | $-0.38 | $-0.38 | 0.0% | $11.9M | $11.0M | -7.5% |
| 5/8/2023 | $-0.34 | $-0.34 | 0.0% | $14.4M | $12.1M | -16.0% |
| 2/27/2023 | $-0.15 | $-0.31 | -106.7% | $23.8M | $13.7M | -42.5% |
| 11/8/2022 | $-0.36 | $-0.35 | +2.8% | $6.8M | $13.1M | +90.7% |
| 8/9/2022 | $-0.35 | $-0.38 | -8.6% | $5.3M | $7.7M | +43.5% |
| 5/10/2022 | $0.51 | $-0.33 | -164.7% | $84.0M | $5.3M | -93.7% |
| 3/23/2022 | $-0.30 | $-0.38 | -26.7% | $6.0M | $2.5M | -58.6% |
| 11/10/2021 | $-0.28 | $-0.28 | 0.0% | $2.5M | $2.5M | -1.3% |
| 8/13/2021 | $-0.23 | $-0.31 | -34.8% | $2.5M | $2.5M | -1.9% |
| 5/12/2021 | — | $-0.18 | — | — | $2.5M | — |
| 4/16/2021 | — | $-0.15 | — | — | $2.6M | — |
| 9/30/2020 | — | $-0.14 | — | — | $862,000 | — |
| 6/30/2020 | — | $-0.11 | — | — | $186,000 | — |
| 3/31/2020 | — | $-0.11 | — | — | $60,000 | — |